View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

Tile Shop Announces Effective Date for Stock Splits and Delisting from...

Tile Shop Announces Effective Date for Stock Splits and Delisting from Nasdaq Capital Market MINNEAPOLIS, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Tile Shop Holdings, Inc. (Nasdaq: TTSH) (“Tile Shop” or the “Company”), a specialty retailer of natural stone, man-made and luxury vinyl tiles, setting and maintenance materials and related accessories, today announced the effective date for the previously announced Stock Splits (as defined below) and the effective date of the Company’s voluntary delisting from The Nasdaq Capital Market. Following the approval of the Company’s stockholders at the spe...

 PRESS RELEASE

MAIA’s Ateganosine Surges Ahead with Breakthrough Momentum as Pivotal ...

MAIA’s Ateganosine Surges Ahead with Breakthrough Momentum as Pivotal Phase 3 Trial Initiates CHICAGO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Ateganosine (THIO, 6-thio-2'-deoxyguanosine), a first-in-class telomere-targeting therapy under development by MAIA Biotechnology (NYSE American: MAIA), appears to be gaining increasing attention in the oncology community as emerging clinical results continue to surpass expectations in advanced non-small cell lung cancer (NSCLC). With the therapy’s Phase 2 trial ongoing and a pivotal Phase 3 program initiated this week, ateganosine is being closely watch...

 PRESS RELEASE

MAIA Biotechnology Announces First Patient Dosed in THIO-104 Phase 3 P...

MAIA Biotechnology Announces First Patient Dosed in THIO-104 Phase 3 Pivotal Trial Evaluating Ateganosine as Third-Line Treatment for Advanced Non-Small Cell Lung Cancer Key milestone achieved as Company advances clinical program to full approval trial of ateganosine sequenced with a checkpoint inhibitor in comparison to chemotherapy CHICAGO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that the first patient ha...

 PRESS RELEASE

MAIA Leadership Continues Insider Buying in 2025 and Trial Data Signal...

MAIA Leadership Continues Insider Buying in 2025 and Trial Data Signals Breakout Potential CHICAGO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- A recent round of open-market purchases marks another display of confidence as the small molecule telomere-targeting cancer therapy by MAIA Biotechnology, Inc. (NYSE American: MAIA) advances through mid- to late-stage clinical development. Newly filed disclosures show that CEO Dr. Vlad Vitoc and other board members acquired approximately 182,445 shares between November 21 and 28, 2025. Insiders’ participation has been viewed by the market as a strong signal...

 PRESS RELEASE

MAIA Takes Aim at a $50B Immunotherapy Market with Breakthrough Telome...

MAIA Takes Aim at a $50B Immunotherapy Market with Breakthrough Telomere-Targeting Approach CHICAGO, Dec. 10, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology (NYSE American: MAIA) – The treatment paradigm for advanced non-small cell lung cancer (NSCLC) is undergoing another shift. After a decade of targeted therapies and checkpoint inhibitors (CPIs) dominating headlines, MAIA believes that a new therapeutic class—telomere-targeting agents—is emerging for the population with substantial unmet medical need: patients without actionable mutations and who no longer respond to CPIs or chemotherapy....

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: December 6, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Tile Shop Announces Special Meeting Results, Stock Split Ratio and Int...

Tile Shop Announces Special Meeting Results, Stock Split Ratio and Intention to Delist from Nasdaq MINNEAPOLIS, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Tile Shop Holdings, Inc. (Nasdaq: TTSH) (“Tile Shop” or the “Company”), a specialty retailer of natural stone, man-made and luxury vinyl tiles, setting and maintenance materials and related accessories, today announced that, at the special meeting of stockholders of the Company held on December 3, 2025 (the “Special Meeting”), the requisite stockholders of the Company approved an amendment to the certificate of incorporation of the Company, as a...

 PRESS RELEASE

The Tile Shop Expands Exclusive Collaboration With Designer Kelli Font...

The Tile Shop Expands Exclusive Collaboration With Designer Kelli Fontana, Adds New Patterned and Porcelain Tile Designs MINNEAPOLIS, Dec. 02, 2025 (GLOBE NEWSWIRE) -- The Tile Shop, the Minnesota-based specialty retailer of natural stone and man-made tiles, today announced new additions to its exclusive collaboration with designer Kelli Fontana, expanding one of the retailer’s top-performing designer collections. Following strong customer demand for standout Kelli Fontana styles like —the company’s current #1 best-selling patterned tile—the new and designs offer fresh opportunities f...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: December 1, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

MAIA Biotechnology Announces Open Market Purchases by CEO and Director...

MAIA Biotechnology Announces Open Market Purchases by CEO and Directors CHICAGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that the CEO and certain members of the Company’s Board of Directors purchased approximately 182,445 shares of MAIA common stock at market price between November 21 and 28, 2025. The average common stock price was $1.06. Vlad Vitoc, M.D., Chairman and CEO of MAIA, purchased 94,300 shares ...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: November 26, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

MAIA Biotechnology Highlights Ongoing Momentum of Ateganosine Clinical...

MAIA Biotechnology Highlights Ongoing Momentum of Ateganosine Clinical Program at SITC 2025 Company confirms 12 patients enrolled in Phase 2 THIO-101 to date as expansion trial adds new countries Posters for Phase 2 and Phase 3 clinical trials available CHICAGO , Nov. 21, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced highlights from two poster presentations delivered at SITC 2025, an annual conference hosted by the Socie...

 PRESS RELEASE

MAIA Biotechnology CEO Presents Telomere Targeting Efficacy at Romania...

MAIA Biotechnology CEO Presents Telomere Targeting Efficacy at Romania’s 2025 Smart Diaspora Conference on Oncology Research and Innovation Company starts enrollment in Romania for Phase 2 THIO-101 Part C study of ateganosine as a treatment for advanced non-small cell lung cancer patients CHICAGO, Nov. 20, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced a presentation by CEO Vlad Vitoc, M.D. at Smart Diaspora 2025, a confer...

 PRESS RELEASE

The Tile Shop Reports Third Quarter 2025 Results

The Tile Shop Reports Third Quarter 2025 Results MINNEAPOLIS, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Tile Shop Holdings, Inc. (Nasdaq: TTSH) (the “Company”), a specialty retailer of natural stone, man-made and luxury vinyl tiles, today announced results for its third quarter ended September 30, 2025. Third Quarter 2025 Summary Net Sales Decreased 1.7%Comparable Store Sales Decreased 1.4% Gross Margin of 62.9%Net Loss of $1.6 Million and Adjusted EBITDA of $2.0 MillionNo Debt Outstanding and $24.1 million of Cash at Quarter-End Management Commentary – Cabell Lolmaugh, CEO “Unit volumes inc...

 PRESS RELEASE

The Tile Shop to Report Third Quarter 2025 Financial Results

The Tile Shop to Report Third Quarter 2025 Financial Results MINNEAPOLIS, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Tile Shop Holdings, Inc. (Nasdaq: TTSH) (the “Company”), a specialty retailer of natural stone, man-made and luxury vinyl tiles, setting and maintenance materials and related accessories, today announced that the Company will release financial results for the third quarter ended September 30, 2025 on Tuesday November 4, 2025, after the close of the financial markets. The Company will not be hosting a conference call.   The Company intends to use its website, , as a means of disclos...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: October 27, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

MAIA Biotechnology Presents Trial in Progress Poster at the 2025 AACR-...

MAIA Biotechnology Presents Trial in Progress Poster at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics First five patients in Part C (expansion) of THIO-101 Phase 2 clinical trial enrolled in Taiwan and Turkey CHICAGO, Oct. 27, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced its recent attendance at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cance...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: October 25, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch